Diabetes Associated Ophthalmic Treatment Market Size, Share, Growth 2034

Diabetes Associated Ophthalmic Treatment Industry Prospective:

The global diabetes associated ophthalmic treatment market size was worth around USD 35.45 billion in 2024 and is predicted to grow to around USD 69.09 billion by 2034, with a compound annual growth rate (CAGR) of roughly 6.90% between 2025 and 2034.

Request Free Sample

Diabetes Associated Ophthalmic Treatment Market: Overview

Diabetes associated ophthalmic treatment refers to a wide range of medical therapies, treatments, and care procedures undertaken to manage vision problems caused or amplified by diabetes. The most common ophthalmic problem that arises due to diabetes is diabetic retinopathy.

However, other eye-related conditions such as cataracts and glaucoma can also be caused or worsened by the blood sugar medical condition. Diabetic retinopathy, for instance, can lead to complete vision loss in patients with diabetes if left untreated or undiagnosed. These conditions can deteriorate a patient’s quality of life; hence, the demand for associated medical treatments is rising.

At present, diabetes-related ophthalmic therapies are of various types, such as laser treatments, vitrectomy surgery, steroid injections, and regular eye exams. During the forecast period, the demand for diabetic associated ophthalmic treatment is expected to grow steadily due to the rising number of diabetic patients worldwide.

In addition, a consistent rate of innovation in treatments and medical procedures, along with increased healthcare expenditure, will promote market revenue during the forecast period. However, factors such as high cost of treatment and limited access to quality medical care in certain parts of the world may pose critical challenges for future growth in the industry.

Key Insights:

• As per the analysis shared by our research analyst, the global diabetes associated ophthalmic treatment market is estimated to grow annually at a CAGR of around 6.90% over the forecast period (2025-2034)
• In terms of revenue, the global diabetes associated ophthalmic treatment market size was valued at around USD 35.45 billion in 2024 and is projected to reach USD 69.09 billion by 2034.
• The diabetes associated ophthalmic treatment market is projected to grow at a significant rate due to the growing number of diabetic patients worldwide.
• Based on the type, the drugs segment is growing at a high rate and will continue to dominate the global market as per industry projections.
• Based on the application, the diabetes retinopathy segment is anticipated to command the largest market share.
• Based on region, Asia-Pacific is projected to dominate the global market during the forecast period.

Diabetes Associated Ophthalmic Treatment Market: Growth Drivers

Growing number of diabetic patients worldwide to propel market expansion rate

The global diabetes associated ophthalmic treatment market is expected to be led by an increasing number of diabetic patients globally. According to the World Health Organization (WHO), more than 830 million people worldwide have diabetes.

The actual number may be higher due to the presence of a large undiagnosed population. Diabetes is a chronic metabolic medical condition that results in high blood sugar levels.

Over time, diabetes can become a serious condition if unchecked or untreated. Diabetes is broadly classified into 4 types: gestational diabetes, type 1 diabetes, type 2 diabetes, and prediabetes. The condition is caused by several factors.

For instance, type 2 diabetes is a result of insulin resistance in the body and can be induced by a lack of physical exercise, hormonal changes, or certain medicines. One of the most common complications associated with diabetes is loss of vision over time.

According to the National Eye Institute, 1 in every 4 diabetic patients suffers from diabetic retinopathy. The number of diabetic patients worldwide is growing at a rapid rate. The changing lifestyle of the population, poor eating habits, and genetic reasons are some of the leading causes of diabetes, resulting in a higher demand for effective diabetes associated ophthalmic treatments.

Growing healthcare expenditure and increased patient awareness work in favor of the market

Healthcare expenditure across the globe is on the rise. The present healthcare infrastructure is unequipped to handle the growing number of patients and the ultimate pressure on the medical community.

In February 2025, reports emerged confirming that the Chinese government had granted a USD 42 million grant to the Rwandan government, which the latter will use for the expansion of the Masaka District Hospital.

Furthermore, the Indian healthcare industry registered investments worth USD 30 billion between 2022 and 2024, according to official reports. The global diabetes associated ophthalmic treatment market will further benefit from the rising rate of patient awareness.

Factors such as increased government awareness programs and access to information through online applications have helped drive patient understanding of treatments for diabetes associated vision problems.

Diabetes Associated Ophthalmic Treatment Market: Restraints

High cost of treatment to emerge as the crucial growth restraining factor

The global diabetes associated ophthalmic treatment industry is expected to be restricted by the high cost of treatment. Certain medical procedures, especially surgical intervention for treating diabetes-induced vision impairment, can be expensive.

For instance, private clinics in the UK may charge between EUR 2000 and EUR 3500 for cataract surgery. The growing healthcare expenses and lack of national insurance policies in certain parts of the world will further inhibit the industry’s final revenue.

Diabetes Associated Ophthalmic Treatment Market: Opportunities

Increasing rate of innovation and new drug development to generate growth opportunities

The global diabetes associated ophthalmic treatment market is expected to generate growth opportunities due to the rising rate of innovation in the industry. Pharmaceutical companies and therapy developers are working consistently to provide more effective diagnostic and treatment plans for treating vision impairment caused by diabetes.

In February 2025, the US Food & Drug Administration (FDA) announced the approval of Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema (DME). The treatment is developed by Roche, a leading pharmaceutical giant. DME is a dominant cause of vision loss in adults with diabetes. Susvimo is a convenient and unique treatment. It will work as an alternative to routine eye injections.

In 2022, the regulatory agency approved Vabysmo by Genentech. It is a novel vascular endothelial growth factor therapy designed to treat age-related macular degeneration and diabetic macular oedema.

Furthermore, medically invasive treatments such as laser surgeries become less painful and more precise, with a reduced rate of invasiveness to deliver higher patient comfort.

Some of the recent advancements in laser therapy include selective retina therapy (SRT) and subthreshold micropulse laser (SMPL), which are known to be highly effective. Other innovations are observed in the form of improved diagnostic capabilities and prevention of the worsening of existing vision-related problems.

Diabetes Associated Ophthalmic Treatment Market: Challenges

Patient compliance and side effects of the treatment to challenge market expansion

The global diabetes associated ophthalmic treatment industry is expected to be challenged by the lack of patient compliance in adhering to the prescribed treatment. For instance, some patients may require frequent eye injections, which can be time- and resource-consuming, especially for older patients.

In addition, side effects of diabetes-related ophthalmic treatments, such as allergic reactions to the medicine or cataract formation, can discourage patients from undergoing the medical care.

Request Free Sample

Diabetes Associated Ophthalmic Treatment Market: Report Scope

Diabetes Associated Ophthalmic Treatment Market: Segmentation

The global diabetes associated ophthalmic treatment market is segmented based on type, application, and region.

Based on the type, the global market segments are devices and drugs. In 2024, the highest growth was listed in the drugs segment, accounting for nearly 55% of the total market share. One of the key reasons is the growing incorporation of anti-Vascular Endothelial Growth Factor (VEGF) therapies used to treat major ophthalmic conditions caused by diabetes. Furthermore, growing regulatory approvals of novel drugs to manage vision impairments in diabetic patients will further renew market revenue.

Based on the application, the diabetes associated ophthalmic treatment industry divisions are diabetes retinopathy, glaucoma, cataract, dry eye syndrome, diabetes associated macular degeneration, and others. In 2024, the highest revenue-generating segment was diabetes retinopathy, contributing to 26.05% of the final revenue. Diabetic retinopathy is the most common complication associated with diabetes. Moreover, increasing medical research in the development of more effective treatments for diabetes retinopathy may further fuel market expansion.

Diabetes Associated Ophthalmic Treatment Market: Regional Analysis

Asia-Pacific to propel market expansion during the forecast period

The global diabetes associated ophthalmic treatment market will be led by Asia-Pacific during the forecast period. India is home to the highest number of diabetic patients in Asia-Pacific as well as on a global scale.

More than 2 million cases of diabetes have been reported in the country in the last few years. China, on the other hand, has the second-highest number of diabetic patients, creating demand for vision-related problems caused by the disease.

The growing regional population, along with the rising demand for quality medical care for people of all economic backgrounds, will promote the market expansion rate.

In April 2025, Dr. Mohan’s Diabetes Specialties Centre (DMDSC) in India announced the launch of a next-generation artificial intelligence (AI)-powered software. The application is designed to detect early signs of retinal damage.

In March 2024, Roche began selling its widely popular drug Vabysmo in the Indian market. Asian countries are witnessing higher investments in healthcare infrastructure, with an increasing number of hospitals and diagnostic centers. Rising support from the regional government toward pharmaceutical companies may further amplify regional market revenue.

Diabetes Associated Ophthalmic Treatment Market: Competitive Analysis

The global diabetes associated ophthalmic treatment market is led by players like:

• Pfizer Inc.
• F. Hoffmann-La Roche Ltd
• Bausch Health Companies Inc.
• EyePoint Pharmaceuticals Inc.
• Johnson & Johnson Services Inc.
• Kodiak Sciences Inc.
• Santen Pharmaceutical Co. Ltd.
• Ocular Therapeutix Inc.
• Novartis AG
• Genentech Inc.
• AbbVie Inc.
• Oxurion NV
• Bayer AG
• Regeneron Pharmaceuticals Inc.
• Alcon Inc.

The global diabetes associated ophthalmic treatment market is segmented as follows:

By  Type

• Devices
• Drugs

By Application

• Diabetes Retinopathy
• Glaucoma
• Cataract
• Dry Eye Syndrome
• Diabetes Associated Macular Degeneration
• Others

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa